drugset
drugset / Trial / NCT00990743

Tolerance and Effect on Intraocular Pressure After Administration of SYL040012

NCT00990743 ↗

Phase 1 Completed 30 enrolled Sylentis, S.A.
NaSingle-groupSingle-blindTreatment

Summary

The purpose of this study is to determine whether SYL040012 is safe for the treatment of ocular hypertension and glaucoma.

Timeline

Start
2009-09
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject bamosiran Unknown — Other

Indications

glaucoma ocular hypertension